Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surges
Vaxcyte's shares {$PCVX} jumped 35% Monday morning after the company announced that its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults, a major step in its quest to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.